According to retaliation Star Pharmaceutical (02196.HK) in response to investor inquiries at the shareholders' meeting, the State Drug Administration's examination and approval of mRNA COVID-19 vaccine "Fubitai" has been basically completed, the expert review has been passed, and is currently stepping up the administrative examination and approval stage.

It is reported that Fosun Pharmaceuticals has started production preparations with BioNTech (BNTX.US) in advance, and once the Fubitai vaccine is approved, it can be supplied to the mainland as soon as possible; according to people familiar with the matter, Fosun is likely to be used as a strengthening needle in the mainland for free vaccination in the future.